Document:

EX-10.10

 Exhibit 10.10 

SECOND AMENDMENT TO LEASE 

THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is dated as of December _, 2011 (the “Effective
Date”) by and between Sonoma Airport Properties LLC, a California limited liability company (“Landlord”), TriVascular, Inc., a California corporation (“TV”) and Boston Scientific Corporation, a Delaware
corporation (“BSC” or “Tenant”). 
 RECITALS: 

WHEREAS, Carmel River, LLC, a Delaware limited liability company, Carlsen Investments, LLC, a California limited liability company, and
Rieger Investments, LLC, a Delaware limited liability company (collectively, “Original Landlord”) entered into that certain Lease Agreement dated June 16, 2005 (the “Original Lease”) with TV as the original
tenant (TV, in that capacity, “Original Tenant”), pursuant to which Original Tenant leased from Original Landlord a total of 110,250 square feet of warehouse and office space located at 3910 Brickway Boulevard, Santa Rosa,
California (the “Premises”). 
 WHEREAS, Original Landlord and Boston Scientific Santa Rosa Corp., a California
corporation (formerly known as TriVascular, Inc., i.e., the same legal entity as the Original Tenant) (“BSSRC”) and BSC entered into that certain Consent, Assignment, First Amendment To Lease and Non-Disturbance Agreement
(the “First Amendment”) dated as of March 28, 2008, pursuant to which (i) BSSRC assigned its right, title and interest under the Original Lease, as the tenant thereunder, to BSC and (ii) other terms and conditions of
the Original Lease were amended. The Original Lease as amended by the First Amendment and this Second Amendment is referenced herein as the “Lease.” 

WHEREAS, BSC subleased the Premises to TV (then known as TriVascular2, Inc., a California corporation) pursuant to that certain
Sublease Agreement dated as of March 28, 2008 (the “Sublease”). 
 WHEREAS, Landlord has succeeded to the
interest of Original Landlord as the owner of the Premises and the landlord under the Lease. 
 WHEREAS, the Original Lease, as
amended by the First Amendment, by its terms expires on February 28, 2013, and the parties desire to extend the term of the Lease and to modify certain other terms and provisions of the Lease and BSC desires to assign the Lease to TV effective
as of March 1, 2013 and TV desires to accept such assignment, all as more particularly set forth herein. 
 NOW, THEREFORE, in
consideration of the mutual covenants and agreements of the parties, and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties agree as follows: 

1. Recitals; Defined Terms. The foregoing recitals are true and are incorporated herein by this reference as though set forth in
full. Unless otherwise expressly defined herein, all initially-capitalized terms used herein shall have the meanings ascribed to them in the Lease. 

2. Assignment of BSC’s Interest in the Lease. Effective as of March 1, 2013, (a) BSC presently and absolutely
assigns all of its right, title and interest as tenant under the Lease to TV, (b) TV accepts such assignment and expressly assumes all obligations under the Lease and (c) TV agrees to be fully liable for the obligations of
“Tenant” under the Lease, including, without limitation, any and all liabilities for any tenant defaults existing as the date of the assignment or otherwise (as between BSC and TV, however, the terms of the Sublease shall prevail regarding
any tenant defaults before the date of the assignment). Notwithstanding anything to the contrary in the Lease or the Sublease, no further agreements shall be necessary to effect the assignment, which will automatically occur on March 1, 2013.
Accordingly, the Sublease will automatically terminate as of 11:59 p.m. on February 28, 2013. BSC will return to TV the Security Deposit (as defined in the Sublease) pursuant to the terms of the Sublease on or before March 31, 2013.
Landlord hereby affirms that (i) as of February 28, 2013, BSC shall be released and relieved of all of its obligations as tenant under the Lease notwithstanding anything to the contrary in 

  
 1 

 
the Lease, (ii) the Guaranty dated June 16, 2005 by BSC in favor of Landlord will terminate on February 28, 2013 and BSC will have no further obligations whatsoever as guarantor,
(iii) the right of TV to assign the Lease or sublease the Premises without Landlord’s consent to a Tenant’s Affiliate pursuant to Section 9.02 of the Lease shall be in full force and effect notwithstanding this assignment and
(iv) the Right of First Refusal to Purchase will still be in full force and effect notwithstanding anything to the contrary contained in the Lease, and may be exercised by TV as tenant (or any Tenant Affiliate, as applicable) on the terms and
conditions set forth in Article 19 of the Lease. 
 3. Term of Lease. The Term of the Lease shall be extended for an additional
period of five (5) years commencing on March 1, 2013, and continuing through February 28, 2018, inclusive (the “Extended Term”). 

4. Monthly Base Rent. The Base Rent for the Extended Term shall be as follows: 

 

					
	 Months
	  	Monthly Rent	 
	 3/1/2013 to 2/28/2014
	  	$	88,200 	($0.80/sf) 
	 3/1/2014 to 2/28/2015
	  	$	90,405 	($0.82/sf) 
	 3/1/2015 to 2/28/2016
	  	$	92,610 	($0.84/sf) 
	 3/1/2016 to 2/28/2017
	  	$	94,815 	($0.86/sf) 
	 3/1/2017 to 2/28/2018
	  	$	97,020 	($0.88/sf) 

 5. Additional Rent. In addition to TV’s obligation to pay the Base Rent as provided above,
(a) Tenant shall be obligated to pay any and all additional rent and other charges payable under the terms of the Lease as computed and provided for under the terms of the Lease (except as otherwise amended by Section 6 of this Amendment)
during the balance of the initial Term and (b) TV as tenant shall be obligated to do so during the entire Extended Term. 
 6.
Free Base Rent Period. In consideration of Tenant’s election to extend the Lease pursuant to this Amendment, Landlord has agreed that the Tenant shall be entitled to a free Base Rent period for the months of October, November and
December of 2011 (the “Free Base Rent Period”). During the Free Base Rent Period, Tenant shall have no obligation to pay any Base Rent but Tenant shall remain obligated to pay all other Additional Rent as required under Article Four
of the Lease (except as otherwise amended by Section 6 of this Amendment). As of the Effective Date, Tenant has already paid Landlord (and TV has paid to Tenant pursuant to the terms of the Sublease) the Base Rent for the months of October,
November and December of 2011 (with such Base Rent payments totaling $257,985.00 or $85,995.00 for each month). Upon written direction from Tenant, Landlord shall provide a check to TV, or any other entity that TV shall designate, refunding the
amount of the Base Rent for the months of October, November and December of 2011 in the total amount of $257,985.00. 
 7. Waiver of
Outstanding Common Area Costs; Revised Estimate of Common Area Costs Effective January 1, 2012. In further consideration of the election to extend the Lease pursuant to this Amendment, Landlord has agreed to waive any obligation Tenant
has to pay any Common Area costs for the years of 2009, 2010 and 2011 over and above the amount of $15,426.59 per month (and TV shall also receive the benefit of this waiver under the Sublease). Thus, for the years of 2009 and 2010, the cumulative
excess amount of Common Area costs (in excess of the $15,426.59 per month estimated cost) previously due in the amount of $61,257.74 is hereby waived. Furthermore, any excess amount of Common Area costs for the year of 2011 (in excess of the
$15,426.59 per month estimate) is also waived. Tenant acknowledges that Tenant shall remain obligated to pay Common Area costs for the year 2011 pursuant to Section 4.05(e) of the Lease, provided, however, that such costs shall in no event
exceed the $15,426.59 per month cost estimate. Landlord and Tenant acknowledge and agree that no waiver of any Common Area costs shall be applicable commencing January 1, 2012, and that the estimated monthly amount of Common Area costs
effective as of January 1, 2012, shall be $18,500.00. 

  
 2 

 8. Option to Renew. TV as tenant (or its assignee or Tenant’s Affiliate, if
applicable) shall have one (1) option to extend the Term of the Lease beyond the Extended Term provided in Section 2 of this Amendment pursuant to the terms and provisions of Article 16 of the Lease except that the parties hereto agree
that said Article 16 is hereby amended to: (i) acknowledge that the additional extended term referenced in this paragraph shall be for the period commencing on March 1, 2018 through February 28, 2023; (ii) the Renewal Notice
Deadline (as referenced in Section A of Article 16) shall be no later than six (6) months before the expiration of the Extended Term (or February 28, 2018); and (iii) the last sentence of Subsection (A)(1) of Article 16 shall be
modified to read in part, “...provided, however, that Base Rent payable during the first year of such extended Term shall in no event be less than $.84 per square foot, increased thereafter as stated herein.” Aside from the option to renew
provided in this Section 7, TV as tenant (or its assignee or Tenant’s Affiliate, if applicable) shall have no further right to extend the term of the Lease. 

9. AS-IS Condition. TV acknowledges that TV has been occupying the Premises pursuant to the Sublease and TV accepts the Premises
in its AS-IS condition and “WITH ALL FAULTS” for the Extended Term and that, except for Landlord’s ongoing maintenance obligations pursuant to Section 6.03 of the Lease, repair obligations pursuant to Article 7 of the Lease and
compliance obligations pursuant to Article 15 of the Lease, Landlord shall have no obligation to improve, remodel, alter, repair, replace or otherwise modify the Premises or provide or pay for any tenant improvements or brokerage commissions during
the Extended Term. 
 10. Status. 

a. Tenant Status. As a material inducement to Landlord entering into this Amendment, Tenant and TV certify to Landlord that as of
the Effective Date: (i) the Lease, as modified hereby, and the Sublease contain the entire agreement between the parties hereto relating to the Premises and that there are no other agreements between the parties relating to the Premises, the
Lease, the Sublease or the Project which are not contained herein or in the Lease or the Sublease; (ii) to the best of Tenant’s and TV’s knowledge, Landlord is not in default in any respect in any of the terms, covenants and
conditions of the Lease; and (iii) to the best of Tenant’s and TV’s knowledge, neither Tenant nor TV has any setoffs, counterclaims or defenses against Landlord under the Lease or the Sublease. 

b. Landlord Status. As a material inducement to Tenant and TV entering into this Amendment, Landlord certifies to Tenant and TV
that as of the Effective Date: (i) the Lease, as modified hereby, and the Sublease contain the entire agreement between the parties hereto relating to the Premises and that there are no other agreements between the parties relating to the
Premises, the Lease, the Sublease or the Project which are not contained herein or in the Lease or the Sublease; (ii) to the best of Landlord’s knowledge, neither Tenant nor TV is in default in any respect in any of the terms, covenants
and conditions of the Lease; and (iii) to the best of Landlord’s knowledge, Landlord has no claims against Tenant or TV under the Lease. 

11. Confidentiality. The parties covenant and agree to keep the terms and conditions of the Lease and this Amendment in
confidence and expressly agree not to disclose the terms of the Lease or this Amendment to any person whatsoever, including, without limitation, the general public; provided, however, that the parties may disclose such information to their
respective employees, attorneys, or accountants provided such recipient agrees to keep such information confidential, as required by this Section 11. 

12. No Broker. Landlord, Tenant and TV each represent and warrant to the others that it has had no dealings with any broker,
finder, or similar person who is or might be entitled to a commission or other fee in connection with this Amendment. Each party shall indemnify, defend, protect and hold harmless the other parties from and against any and all obligations or
liabilities to pay any real estate broker’s commission, finder’s fee, or other compensation to any person or entity arising from or in connection with this Amendment which results from any act or agreement of such party. 

  
 3 

 13. Conflict. This Amendment is and shall be construed as a part of the Lease. In
case of any inconsistency between this Amendment and the Lease, the provisions containing such inconsistency shall first be reconciled with one another to the maximum extent possible and, then to the extent of any remaining inconsistency, the terms
of this Amendment shall be controlling. 
 14. Force and Effect. Except as set forth in this Amendment, the terms and
conditions of the Lease shall remain unchanged and in full force and effect. 
 15. Counterparts; Authority; Electronic
Signatures. The parties agree that this Amendment may be executed in multiple counterparts which, when signed by all parties, shall constitute a binding agreement. The parties further represent and warrant that each natural person who is
executing this Amendment on its behalf has the full power and authority to execute this Amendment and to bind it to the terms hereof. Signatures to this Amendment transmitted by telecopy or electronic mail shall be valid and effective to bind the
party so signing. Each party agrees to promptly deliver an execution original of this Amendment with its actual signature to the other party, but a failure to do so shall not affect the enforceability of this Amendment, it being expressly agreed
that each party to this Amendment shall be bound by its own telecopied or electronically-mailed signature and shall accept the telecopied or electronically-mailed signature of the other party to this Amendment. 

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date indicated above. 

 

									
	LANDLORD:	  		  	TV:
			
	SONOMA AIRPORT PROPERTIES LLC,	  		  	TRIVASCULAR, INC.,
	a California limited liability company	  		  	a California corporation
					
	By:	 	 /s/ RON PROFILI
	  		  	By:	 	 /s/ Michael Kramer

	Name:	 	RON PROFILI	  		  	Name:	 	Michael Kramer
	Title:	 	MANAGING MEMBER	  		  	Title:	 	Chief Financial Officer
				
	BSC:	  		  		 	
				
	BOSTON SCIENTIFIC CORPORATION,	  		  		 	
	a Delaware corporation	  		  		 	
					
	By:	 	 /s/ ED ZIELINSKI
	  		  		 	
	Name:	 	ED ZIELINSKI	  		  		 	
	Title:	 	VICE PRESIDENT GLOBAL	  		  		 	
		 	REAL ESTATE AND FACILITIES	  		  		 	

  
 4EX-10.11

 Confidential Materials omitted and filed separately with the Securities and
Exchange Commission. 
 Three asterisks denote omissions. 

Exhibit 10.11 
 EXCLUSIVE
LICENSE AGREEMENT 
 This Exclusive License Agreement (the Agreement) is made as of March 28, 2008 (the
Effective Date) by and between (i) a California corporation that will be known as Trivascular 2, Inc. (after a name change to occur shortly after the Effective Date), is currently known as Boston Scientific Santa Rosa Corp. and
was previously known as TriVascular, Inc. (Licensor), and (ii) Boston Scientific Scimed, Inc., a Minnesota corporation (together with its Affiliates, Licensee). 

WHEREAS, (i) BOSTON SCIENTIFIC CORPORATION, a Delaware corporation, (ii) BOSTON SCIENTIFIC SCIMED, INC., a Minnesota
corporation, and (iii) TV2 HOLDING COMPANY, a Delaware corporation. (Buyer) have entered into that certain Stock Purchase Agreement dated as of the Effective Date (Purchase Agreement)
pursuant to which, on the Effective Date, Buyer purchased all of the outstanding shares of capital stock of Licensor; 

WHEREAS, as a result of the Purchase Agreement, Licensor is the owner of the “TriVascular Intellectual Property” (as defined in the
Purchase Agreement); 
 WHEREAS, Licensor has obtained additional intellectual property rights from Licensee and/or its
Affiliates as a result of that certain Nonexclusive License Agreement and Covenant Not to Sue (License and Covenant Agreement) and that certain Know-How Assignment Agreement (Know-How Agreement), both dated as of the Effective Date; and 
 WHEREAS,
Licensee desires to obtain a license to use certain intellectual property rights of Licensor, and Licensor has agreed to grant to Licensee such license in accordance with the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the premises and mutual promises and agreements hereinafter set forth, the parties hereto agree as
follows: 
  

	1.	DEFINITIONS.  

 The following terms, when used herein, have the meanings set forth below.
Capitalized terms used herein and not otherwise defined shall have the meanings assigned thereto in the Purchase Agreement, the License and Covenant Agreement, and the Know-How Agreement. 

Affiliate means, with respect to the Person to which it refers, another Person that directly or indirectly,
through one or more intermediaries, controls, is controlled by or is under common control with, such first Person. For this purpose, “control” means the ownership of fifty percent (50%) or more of the voting securities entitled to
elect the directors or management of the Person, or the actual power to elect or direct the management or policies of the Person by law, contract, or otherwise. 

Fill/Film Know-How means that Licensed Know-How designated as Fill/Film
Know-How in Exhibit A attached hereto. 
 Intellectual Property Rights
means intellectual property or proprietary rights of any description including (a) rights in any patent, patent application, including any provisionals, continuations, divisionals, continuations-in-part, extensions, renewals, reissues, revivals
and reexaminations, any national phase PCT applications, any PCT international applications, and all foreign counterparts of any of the foregoing, (b) rights in any copyright, industrial design, URL, domain name, trademark, service mark, logo,
trade dress or trade name, (c) related registrations and applications for registration, (d) trade secrets, moral rights or publicity rights, (e) inventions, discoveries, improvements, know-how,
techniques, methodologies, designs or data, whether or not patented, patentable, copyrightable or reduced to practice, and (f) goodwill related to any of the foregoing. 

 

  
 1 

 Licensed Field means any and all medical device fields or medical device
applications outside the Retained Field. 
 Licensed Know-How means the know-how, trade secrets, inventions, discoveries, data
and technical information listed in Exhibit A attached hereto, including the Fill/Film Know-How. 

Licensed Patent(s) means Old Licensed Patents and New Licensed Patents. 

Licensed Product(s) means Old Patent Licensed Products and New Patent Licensed Products. 

Licensed Technology means, individually and collectively, (a) the Old Licensed Patents, and (b) the Licensed Know-How. 
 New Licensed Patent means: (i) the Licensee Patent Filings, and
(ii) each of the following solely to the extent directed to Existing Assigned Know-How Inventions: (a) all patent applications filed by or on behalf of Licensor under the Know-How Agreement; (b) any patent application(s) filed as a continuation, division, or continuation-in-part (solely to the extent not directed to new matter) of the patent application(s) described in clause
(a), patents issuing from the patent application(s) described in clauses (a)-(b) and any reissues, reexaminations and extensions of patents described in clauses
(a)-(b); and (c) any foreign counterpart to the patent(s) and patent application(s) described in clauses (a)-(b) (including divisions, continuations,
confirmations, additions, renewals or continuations-in-part of such patent applications), patents issuing therefrom and reissues, reexaminations and extensions thereof. 

New Patent Licensed Product means any product, part or other material, process or service, the identification, discovery,
research, development, production, use, marketing, offer for sale, distribution, import, export or sale of which, absent the license granted pursuant to this Agreement, would constitute an infringement of the New Licensed Patents. 

New Patent Non-Exclusive Licensed Field means endovascular repair of iliac aneurysms, dissections and/or trauma,
including all products designed to be implanted solely in the iliac excluding devices that are (a) implanted both in (or partially in each of) any portion of the aorta (to avoid doubt, the aorta includes both abdominal aortic and
thoracic aortic blood vessels), and the iliac; and/or (b) modular devices (or components thereof) that are labeled for use together with (or as part of) any device (or portion of a device) that is implanted in any portion of the aorta (to
avoid doubt, the aorta includes both abdominal aortic and thoracic aortic blood vessels). 
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

  
 2 

 Old Licensed Patent(s) means: (a) the patents and patent applications listed
in Schedule 1.01(c)(i) of the Purchase Agreement; (b) any patent application(s) filed as a continuation, division, or continuation-in-part (solely to the extent not directed to new matter) of the patent application(s) described in clause
(a), patents issuing from the patent application(s) described in clauses (a)-(b) and any reissues, reexaminations and extensions of patents described in clauses (a)-(b); and (c) any foreign counterpart to the patent(s) and patent
application(s) described in clauses (a)-(b) (including divisions, continuations, confirmations, additions, renewals or continuations-in-part of such patent applications), patents issuing therefrom and reissues, reexaminations and extensions
thereof. 
 Old Patent Licensed Product(s) means any product, part or other material, process or service, the identification,
discovery, research, development, production, use, marketing, offer for sale, distribution, import, export or sale of which, absent the license granted pursuant to this Agreement, would constitute an infringement or misappropriation of the Licensed
Technology. Notwithstanding the foregoing, Old Patent Licensed Product(s) excludes all medical devices (other than ***) with a ***. To be clear, the “***” shall exclude states achieved through use of a device outside the reasonable
contemplation of the parties (as examples that shall not be deemed limiting, “reasonably contemplated” use of a device includes (i) all uses described in documentation, marketing materials or published literature for such device and
(ii) all uses of such device that would reasonably be expected to be made in reasonable and customary medical practice). The purpose of the *** restriction provided above, and the parties’ intent in including it, is to reduce the potential
for off-label use of Old Patent Licensed Product(s) labeled for the Licensed Field, by excluding from the definition of “Old Patent Licensed Product” devices that are most likely to be physically capable of being used off-label for the
Retained Field. 
 Licensee Patent Filings means: (a) the patents and patent applications listed in Schedule
1.01(c)(ii) of the Purchase Agreement; (b) any patent application(s) filed as a continuation, division, or continuation-in-part (solely to the extent not directed to new matter) of the patent application(s) described in clause (a), patents
issuing from the patent application(s) described in clauses (a)-(b) and any reissues, reexaminations and extensions of patents described in clauses (a)-(b); and (c) any foreign counterpart to the patent(s) and patent application(s)
described in clauses (a)-(b) (including divisions, continuations, confirmations, additions, renewals or continuations-in-part of such patent applications), patents issuing therefrom and reissues, reexaminations and extensions thereof. 

Person means any individual, corporation, partnership, limited liability company, firm, joint venture, association, joint-stock
company, trust, unincorporated organization, governmental entity or other entity. 
 Regulatory Approval means receipt of
final written approval from the United States Food and Drug Administration or final written registration or approval for a CE Mark allowing the marketing and sale of products covered by Licensed Patents by Licensor in the Retained Field. 

Retained Field means endovascular repair of aneurysms, dissections and/or trauma for aortic, thoracic and iliac blood vessels,
including products designed to be implanted in the iliac. 
 *** = Portions of this exhibit have been omitted pursuant to a request for
confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

  
 3 

	2.	GRANT OF RIGHTS. 

 2.1. Old Patent License Grant. Subject to the terms and
conditions of this Agreement and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Licensor hereby grants to Licensee, and Licensee hereby accepts: 

(a) an irrevocable (except as otherwise provided in Sections 3 and 6), exclusive, worldwide, royalty-free, fully paid-up right and license,
including the right to sublicense (solely in a manner that complies with Section 2.3), to use the Old Licensed Patents to the extent necessary or useful to develop, have developed, make, have made, use, have used, distribute, promote, market,
offer for sale, sell, have sold, import and export Old Patent Licensed Products, solely within the Licensed Field; 
 (i) Notwithstanding
the *** restriction of the definition of Old Licensed Patent Product, in the unanticipated case where Licensee wishes to develop for the Licensed Field a medical device (other than ***) covered by the Old Licensed Patents that does not
comply with the *** restriction of the definition of Old Patent Licensed Product (“Non-Compliant Covered Device”) that Licensee believes has physical characteristics that would prevent it from being used off-label for the Retained Field,
Licensee may seek Licensor’s prior written permission, on a Non-Compliant Covered Device-by-Non-Compliant Covered Device basis, for the particular Non-Compliant Covered Device to be included in the Old Patent Licensed Products.
Licensee may seek Licensor’s prior written consent as follows: to seek such permission, Licensee shall notify Licensor in writing explicitly stating that the notice is to seek permission to include a Non-Compliant Covered Device
in the Old Patent Licensed Products. In such notice, Licensee shall include detailed, complete designs and plans for such Non-Compliant Device. Licensor agrees that any information provided by Licensee to Licensor in accordance with this
Section 2.1(a)(i) shall constitute Confidential Information of Licensee, which shall be treated in accordance with Section 8 of this Agreement. Licensor shall have ninety (90) days to respond whether Licensor agrees
to include such Non-Compliant Covered Device among the Old Patent Licensed Products. If in Licensor’s good faith opinion such Non-Compliant Covered Device presents no medically reasonable possibility of use (including off-label use) in the
Retained Field, Licensor shall not unreasonably withhold its consent. Any Non-Compliant Covered Device for which Licensor provides its explicit written consent shall be an “Old Patent Licensed Product.” 

2.2. Know-How and New Patent License Grant. Subject to the terms and conditions of this Agreement and for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Licensor hereby grants to Licensee, and Licensee hereby accepts: 

(a) Fill/Film Know-How and Related New Patents. an irrevocable (except as otherwise provided in Sections 3 and 6), exclusive,
worldwide, royalty-free, fully paid-up right and license, including the right to sublicense (solely in a manner that complies with Section 2.3), to use the Fill/Film Know-How, and any New Licensed Patent to the extent directed to the Fill/Film
Know-How, to the extent necessary or useful to develop, have developed, make, have made, use, have used, distribute, promote, market, offer for sale, sell, have sold, import and export products solely within the Licensed Field; and 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has
been filed separately with the Commission. 
  
  

  
 4 

 (b) Other Licensed Know-How. an irrevocable (except as otherwise provided in Sections 3
and 6), worldwide, royalty-free, fully paid-up right and license, including the right to sublicense (solely in a manner that complies with Section 2.3), to use the Licensed Know-How outside of the Fill/Film Know-How (except to the extent
claimed in any New Licensed Patent directed to such Licensed Know-How outside of the Fill/Film Know-How), to the extent necessary or useful to develop, have developed, make, have made, use, have used, distribute, promote, market, offer for sale,
sell, have sold, import and export medical device products solely other than each of (i) the AAA Product Class, (ii) the Thoracic Product Class, and (iii) Adjunctive Product Class, but excluding in the case of (iii) thoracic
cuffs not labeled for use as a component of the AAA Product Class or the Thoracic Product Class, as those terms (in (i)-(iii)) are defined (or described) in Exhibit B of the License and Covenant Agreement (collectively
“Excluded-From-Boston-General-Know-How-License Products”); such license shall be exclusive in the Licensed Field and non-exclusive in the Retained Field; and 

(c) New Licensed Patents other than Fill/Film New Licensed Patents. an irrevocable (except as otherwise provided in Sections 3 and 6),
worldwide, royalty-free, fully paid up right and license, including the right to sublicense (solely in a manner that complies with Section 2.3), to use any New Licensed Patent, excluding any New Licensed Patent referred to in
Section 2.2(a), to the extent necessary or useful to develop, have developed, make, have made, use, have used, distribute, promote, market, offer for sale, sell, have sold, import and export New Licensed Patent Products solely within the
Licensed Field and the New Patent Non-Exclusive Licensed Field; such license shall be exclusive in the Licensed Field, and non-exclusive in the New Patent Non-Exclusive Licensed Field. 

2.3. Sublicenses. Each of the license rights granted to Licensee in Sections 2.1 and 2.2 shall include the right to grant sublicenses
solely within the scope of such license right set forth in Sections 2.1 and 2.2 (and subject to all restrictions as to field and product that are incorporated into the applicable underlying license grant set forth in Section 2.1 or 2.2).
Licensee shall include in each such sublicense agreement provisions at least as protective of Licensor (and restrictive of the sublicensee) as the terms and conditions of this Agreement, including provisions at least as protective of Licensor (and
restrictive of the sublicensee) as Section 2.4. 
 2.4. Reservation of Rights. Except as expressly set forth herein, this
Agreement does not grant to Licensee any right, title, interest, ownership or license, by implication, estoppel or otherwise, to any Intellectual Property Rights of Licensor. Without limiting the generality of the foregoing, under no circumstances
will the license grants of Section 2.2 be used to imply a license under the Old Licensed Patents for any product other than Old Patent Licensed Products. 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has
been filed separately with the Commission. 
  

  
 5 

 Licensee and its Affiliates shall not (x) clinically develop through human studies (i.e.,
sponsor, conduct or run a human clinical trial) for a period of ***, or (y) commercialize a product, in each case covered by (i) ***; (ii) ***; or (iii) *** (other than those of (ii)) in fields outside ***. 

Title to the Old Licensed Patents and New Licensed Patents will at all times remain vested in Licensor and nothing in this Agreement shall be
construed to prohibit or restrict Licensor’s right to sell, transfer, assign or encumber any of the Old Licensed Patents and New Licensed Patents, subject to the licenses granted to Licensee hereunder, or except as otherwise set forth herein.

 2.5. Sales into Retained Field. Licensor and Licensee shall promptly (within 30 days) notify each other upon becoming aware that
Old Patent Licensed Products are being used off-label in the Retained Field, or that New Patent Licensed Products are being used off-label in the Retained Field (other than in the New Patent Non-Exclusive Licensed Field). If Licensee becomes aware
of any such off-label use, Licensee shall use reasonable efforts to prevent such use, including notice to physicians and hospitals in writing that such use is not approved. 
  

	3.	BANKRUPTCY. 

 Licensor agrees that the rights to the Licensed Technology and New Licensed
Patents licensed by Licensor to Licensee as set forth herein constitute “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code and that the Agreement shall be governed by Section 365(n) of the Bankruptcy
Code. If Licensor voluntarily or involuntarily becomes subject to the protection of the Bankruptcy Code, and Licensor or the trustee in bankruptcy rejects the Agreement under Section 365 of the Bankruptcy Code, Licensee shall have the right to:
(a) treat the Agreement as terminated; or (b) retain Licensee’s rights under the Agreement, specifically including, without limitation, the right to exercise its rights granted therein to the Licensed Technology and/or New Licensed
Patents. 
  

	4.	REPRESENTATIONS AND WARRANTIES. 

 4.1. Representations. Each of Licensee and
Licensor hereby represents and warrants to the other party that: (a) it is a corporation duly organized and validly existing under the laws of the applicable state of its incorporation, and has all requisite power and authority to execute,
deliver and perform this Agreement and to consummate the transactions contemplated hereby; (b) this Agreement has been duly authorized, executed and delivered by such party and it constitutes the legal, valid and binding obligations of such
party, and it is enforceable against such party in accordance with its terms, except to the extent such enforceability may be limited by bankruptcy, reorganization, insolvency or similar laws of general applicability governing the enforcement of the
rights of creditors; and (c) neither the execution, delivery and performance of this Agreement nor the consummation by such party of the transactions contemplated hereby will violate or conflict with or constitute a default under any
contractual obligation of such party, or any judgment, order or decree applicable to, or binding upon, such party. In Licensor’s case, the representation and warranty contained in the foregoing clause (a) is subject to Licensee having
effectively caused all TriVascular Intellectual Property (as defined in the Purchase Agreement) to be conveyed to Licensor pursuant to the Purchase Agreement 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has
been filed separately with the Commission. 
  

  
 6 

 
and to Licensee having effectively caused all Existing Assigned Know-How Inventions (as defined in the Know-How Agreement) to be conveyed to Licensor pursuant to the Know-How Agreement. Licensee
further represents and warrants that, other than the Licensee Patent Filings, Licensee has not since June 1, 2006 filed (or had filed on their behalf) any patent application directed to any invention that would be Assigned Know-How under the
Know-How Agreement. The sole and exclusive remedy for any breach of the representation and warranty set forth in the preceding sentence shall be that Licensor shall own any such patent application that has been filed the existence of which makes
such representation and warranty untrue, and Licensee hereby assigns any and all such patent applications (together with their patent progeny as described in (b)—(c) of the definition of “Licensee Patent Filings” in this
Agreement) to Licensor. Any and all such patent applications thus assigned from Licensee to Licensor shall be automatically listed in Schedule 1.01(c)(ii) to the Purchase Agreement (and thus licensed to Licensee as and to the extent provided in this
Agreement). 
 4.2. Disclaimer. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTION 4.1 OF THIS AGREEMENT, NEITHER
PARTY MAKES ANY OTHER EXPRESS OR IMPLIED WARRANTY AS TO THE LICENSED TECHNOLOGY OR NEW LICENSED PATENTS INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, QUIET
ENJOYMENT, QUIET POSSESSION, OR ANY WARRANTIES IMPLIED FROM ANY COURSE OF DEALING OR USAGE OF TRADE, AND HEREBY DISCLAIMS THE SAME. Without limiting the foregoing, this Agreement and the licenses granted herein does not and shall not be interpreted
or construed to include: (a) any representation or warranty as to the validity, enforceability or scope of the Licensed Technology or New Licensed Patents, (b) any requirement to file any patent application or secure or maintain any
patent, (c) any obligation to furnish any technical or support information, and/or (d) any license or rights by implication or estoppel. 

4.3. Export. Licensee acknowledges and agrees that it shall not export or re-export, directly or indirectly (including via remote
access), the Licensed Technology, the New Licensed Patents or the Licensed Products, as the case may be, or other information or materials it receives pursuant to this Agreement to any country for which the United States or any other relevant
jurisdiction requires any export license or other governmental approval at the time of export without first obtaining such license or approval. 
  

	5.	PATENT PROSECUTION; ENFORCEMENT. 

 5.1. Prosecution. 

(a) General. Licensor shall have the sole right, but not the obligation, to prepare, file (including foreign filing decisions),
prosecute, maintain, obtain extensions, and conduct all other business before governmental patent offices (Prosecution), with respect to the Licensed Patents at its expense and in its sole and absolute discretion, subject to subsection
(b) below. 
 *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version
of this exhibit has been filed separately with the Commission. 
  

  
 7 

 (b) Cooperation. Licensor shall provide Licensee with copies of all patent
applications and other related material submissions and correspondence with any patent authorities with respect to the Prosecution of the Licensed Patents, so as to allow a reasonable period of time for review by Licensee. Licensor will notify
Licensee, and will provide Licensee with an opportunity to consult with Licensor and its counsel regarding any material actions to be taken or not taken in connection with Prosecution of the Licensed Patents, with respect to the Licensed Field (all
such actions to be taken or not taken, Prosecution Actions). Licensor shall take into consideration the reasonable requests of Licensee regarding Prosecution Actions (other than for Prosecution Actions that only affect filings
that are inherently limited to the Retained Field). 
 The parties acknowledge that if, and only if, rules proposed and promulgated recently
(as of the Effective Date) by the United States Patent and Trademark Office, but which are not currently in effect as of the Effective Date, ultimately become effective in a form that is not materially different from those proposed and promulgated
as of the Effective Date (or if other rules that contain similar limitations on continuations and claims ultimately become effective), .certain limitations would be placed on the numbers of applications, claims and other matters relating to the
Prosecution of patent families and related patent families (the Proposed Rules). (As an example that shall not be deemed limiting, such rules limit the overall number of independent claims, dependent claims and continuations
that may be filed in a given patent family (and across certain related patent families).) Because of these changes, any abandonment of a Licensed Patent filing may be important to Licensor’s overall strategy for its portfolio to maximize the
value and issuance of the Licensed Patents. Allowing Licensee to pick up and prosecute applications that Licensor would otherwise abandon could harm or hamper such strategy. Accordingly, if Licensor intends to abandon or let lapse any Licensed
Patent, and, in the event the Proposed Rules have become effective, solely if Licensor has determined in its discretion that continued Prosecution of such Licensed Patent will not present any risk of harm to Licensor’s overall strategy for
Prosecution of the applicable patent family or related patents, Licensor shall notify Licensee of this determination and allow Licensee to maintain at its own expense such Licensed Patent. In addition, Licensor may, in its sole discretion, elect to
assign any such Licensed Patent to Licensee. To be clear, the foregoing rights of Licensee to participate in the Prosecution of Licensed Patents shall not extend to (a) Prosecution of filings that are inherently limited to the Retained Field,
nor (b) pre-filing activity associated with the first priority filing of any New Licensed Patent. 
 Prosecution of the Licensed
Patents shall be at Licensor’s cost and expense, except that (a) in the event that Licensor takes any Prosecution Action solely at the request of Licensee, Licensee shall pay all costs, expenses and fees reasonably incurred in taking such
action, and (b) all Prosecution by Licensee under the foregoing paragraph shall be at Licensee’s sole expense. Licensee shall fully cooperate with Licensor, at Licensor’s request, in connection with the Prosecution of the Licensed
Patents, and in any other proceedings before a patent official or office (in each case solely to the extent that the cooperation of Licensee’s personnel is uniquely helpful to the foregoing (i.e., the assistance could not be performed by any
other Person) and does not interfere with such personnel’s regular duties with Licensee). 
 *** = Portions of this exhibit have been
omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

  
 8 

 5.2. Enforcement. 

(a) Duty to Notify. Each of Licensor and Licensee shall promptly inform the other in writing of any infringement or
misappropriation of the Licensed Technology and/or the New Licensed Patents in the Licensed Field by a third party of which it has knowledge and shall provide the other with any readily available information relating to such infringement or
misappropriation. 
 (b) Outside the Licensed Field. In the event that any Person is infringing or misappropriating the
Licensed Technology and/or the New Licensed Patents outside of the Licensed Field, Licensor shall have the sole right, but not the obligation, to institute, prosecute and control legal proceedings to prevent or restrain such infringement or
misappropriation, at its expense. Licensor may collect and retain for its own use all damages, profits, settlements and awards of whatever nature recoverable from such proceedings. Licensee agrees to assist in the prosecution of such proceedings as
reasonably requested solely to the extent that the cooperation of Licensee’s personnel is uniquely helpful (i.e., the assistance could not be performed by any other Person) and does not interfere with such personnel’s regular duties with
Licensee, and Licensor shall reimburse Licensee for all reasonable expenses incurred in providing such assistance to Licensor. Licensee shall not otherwise have the right to participate in such proceedings. 

(c) Within the Licensed Field. 

(i) In the event that any Person is infringing or misappropriating the Licensed Technology and/or New Licensed Patents solely within the
Licensed Field, then solely if the infringing or misappropriating product(s) and activity(ies) are medical device product(s) (and/or commercial activities with respect to such medical device product(s)) that is (or are) approved and on the market
and competes (or compete) with any Licensee medical device product that is on the market, within an indication for which both (or all of) the allegedly infringing or misappropriating product(s) and the Boston product are labeled
(Competitive Infringement), Licensee shall have the first right, but not the obligation, to institute, prosecute and control legal proceedings to prevent or restrain such infringement or misappropriation, at its own expense, in a
manner consistent with the remainder of this Section 5.2. If Licensee wishes to initiate such legal proceedings, Licensee shall first notify Licensor in writing. Licensee’s notice must reasonably demonstrate that the infringement or
misappropriation is Competitive Infringement, and that it is occurring solely within the Licensed Field. Licensor shall respond to Licensee’s notice in good faith within 30 days. Once Licensee receives confirmation from Licensor that Licensee
is entitled to proceed to bring such legal proceedings (or if Licensor does not object within such thirty (30) days), then Licensee may proceed with such legal proceedings. Licensee’s conduct of such legal proceedings must comply with
Section 5.2(i). Licensee may collect and retain for its own use all damages, profits, settlements and awards of whatever nature recoverable from such proceedings. Licensor agrees to assist in the prosecution of such proceedings as reasonably
requested, and Licensee shall reimburse Licensor for all reasonable expenses incurred in providing such assistance to Licensee. Licensor may participate in such proceedings with its own counsel, at its sole cost and expense. 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has
been filed separately with the Commission. 
  

  
 9 

 (ii) If Licensee (X) does not demonstrate that the infringement or misappropriation is
Competitive Infringement, or (Y) decides that it will not institute proceedings to prevent or restrain any such infringement or misappropriation (or fails to do so within one hundred eighty (180) days of notification of such infringement
or misappropriation), then Licensor shall have the right, but not the obligation, to institute, prosecute and control legal proceedings, utilizing counsel of its own choice, at its expense. Licensee agrees to assist in the prosecution of such legal
proceedings as reasonably requested and Licensor shall reimburse Licensee for all reasonable expenses incurred in providing such assistance. Licensee shall not otherwise have the right to participate in such proceedings. With respect to such
proceedings that Licensor institutes or prosecutes pursuant to this Section 5.2(c)(ii), any recoveries from such proceedings shall first be used to reimburse the parties for the costs and expenses associated with the proceedings, and the
balance shall be shared between the parties with Licensee receiving twenty percent (20%) of the balance and Licensor retaining eighty percent (80%) of the balance. 

(d) Within and outside the Licensed Field. 

(i) In the event that any Person is infringing or misappropriating the Licensed Technology and/or New Licensed Patents both within and outside
the Licensed Field, Licensor shall have the first right, but not the obligation, to institute, prosecute and control legal proceedings to prevent or restrain such infringement or misappropriation, at its own expense. In the event that Licensor
elects to initiate legal proceedings in accordance with the preceding sentence, Licensor shall be required to deliver notice of such election to Licensee. Licensee shall assist in the prosecution of such proceedings as reasonably requested by
Licensor at Licensor’s expense, and may participate in such proceedings with its own counsel, at its sole cost and expense. Notwithstanding the foregoing participation rights of Licensee, Licensor shall retain sole control over the proceedings
and any settlement thereof, in its sole discretion, subject to the provisions of Section 5.2(e) below. In any such proceeding the parties shall seek to have the relevant court allocate damages attributable to sales of Licensed Products by the
infringer both within and outside of the Licensed Field. 
 Any recoveries from such proceedings shall first be used to reimburse the
parties for any unreimbursed costs and expenses associated with the proceedings (including amounts used to reimburse the other party for expenses incurred by the other party) in accordance with this Section 5.2. The balance shall be allocated
between the parties such that Licensee shall receive an amount equal to the percentage of the damages attributed by the court to infringement within the Licensed Field. Licensor shall retain the remaining balance of damages. If the infringement is
not resolved through litigation or the court fails to allocate damages in accordance with infringing activities within the Licensed Field and outside the Licensed Field, the parties shall negotiate in good faith regarding the portion of the recovery
remaining after reimbursement of all unreimbursed expenses of the parties that is allocable to each party having regard to the respective lost profits or royalties of each party based on sales of Licensed Products by the infringer within the
Licensed Field and outside the Licensed Field. 
 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  
  

  
 10 

 (ii) In the event Licensor decides that it will not institute proceedings to prevent or restrain
any infringement or misappropriation of the Licensed Technology and/or New Licensed Patents occurring both within and outside of the Licensed Field, or fails to do so within one hundred eighty (180) days of notification of such infringement or
misappropriation, or otherwise fails to prevent such further infringement or misappropriation within such 180-day period, Licensee shall have the right, but not the obligation, to institute, prosecute and control legal proceedings, in
Licensor’s name, utilizing counsel of its own choice, at its expense but with respect to such infringement or misappropriation within the Licensed Field and solely against Competitive Infringement. Licensor agrees to assist in the
prosecution of such legal proceedings as reasonably requested and Licensee shall reimburse Licensor for all reasonable expenses incurred in providing such assistance. Licensor may participate in such proceedings with its own counsel at its sole cost
and expense. Licensee shall not settle any such proceedings, or take any action in connection with such proceedings that would affect the validity of the Licensed Patents, without the prior written consent of Licensor. Any recoveries from such
proceedings shall first be used to reimburse the parties for the costs and expenses associated with the proceedings, and the balance shall be retained by Licensee. In no event shall Licensee be entitled to prosecute any infringement or
misappropriation outside of the Licensed Field, or be entitled to receive any recoveries in respect of such infringement. 
 (e) Any party
that elects to institute, prosecute and control any legal proceeding in accordance with this Section 5.2 shall have the right to settle any such proceedings by granting a license to the infringer and any royalties paid in consideration for same
shall be apportioned as provided in this Section 5.2; provided that, in the case of Licensee, any such license shall be limited to the Licensed Field, and in the case of Licensor, Licensor may not grant a license, covenant not to sue, or
similar right to practice the Licensed Technology and/or New Licensed Patents in the Licensed Field, without Licensee’s consent, which may be withheld for any reason or for no reason by Licensee in its sole discretion. 

(f) No settlement or consent judgment, or other voluntary final disposition of any suit that adversely affects the Licensed Technology and/or
the New Licensed Patents, may be entered into without the consent of Licensor, which consent shall not be unreasonably withheld, conditioned or delayed. If the legal proceeding relates to infringement within the Licensed Field (whether solely within
the Licensed Field or both within and outside of the Licensed Field), then no settlement or consent judgment or other voluntary final disposition of the legal proceeding that adversely affects Licensee’s exclusive rights under the Licensed
Technology and/or New Licensed Patents within the Licensed Field may be entered into without the consent of the Licensee, which consent shall not be unreasonably withheld, conditioned or delayed. 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has
been filed separately with the Commission. 
  

  
 11 

 (g) Subject to the provisions of Sections 2.1 and 5.2(c)-(f), in the event that a declaratory
judgment action alleging invalidity is filed, or in the event that any counterclaim or response by a Person in connection with an enforcement action undertaken by Licensee is filed, Licensor, at its initial option, shall have the right, but not the
obligation, within thirty (30) days after notification of same, to participate in and, subject to Section 5.2(i) below, control the defense of the action, at Licensor’s expense. 

(h) In any suit that either party may institute as described in this Section 5, or in any declaratory judgment action alleging invalidity
or non-infringement in connection with this Agreement brought against Licensee or Licensor in connection with this Agreement, the other party shall, at the request and expense of the party initiating or defending the suit or action, cooperate and
assist in all reasonable respects, having its employees testify when requested and making available relevant records, papers, information, specimens and the like. 

(i) Licensee shall not make any admission as to invalidity or unenforceability of any Licensed Patent, or that any claim of the Licensed
Patents should be narrowly construed, without Licensor’s advance written consent, which Licensor may withhold in Licensor’s reasonable discretion. Furthermore, recognizing that strategy in legal actions that Licensee is allowed to pursue
under this Section 5.2 may affect the Licensed Patents as applicable outside the Licensed Field, Licensee shall notify Licensor, and provide Licensor with an opportunity to consult with its counsel and Licensee regarding, any actions to be
taken or not taken in such legal proceedings relating to claim construction and validity that are relevant to or may affect the Retained Field (as an example that shall not be deemed limiting, claim construction proceedings). With respect to these
matters, Licensee must incorporate Licensor’s reasonable comments and follow Licensor’s reasonable overall strategy for the Licensed Patents. The provisions of this Section 5.2(i) and the limitation on Licensee’s right to enforce
the Licensed Patents in the Licensed Field to be solely against Competitive Infringement set forth above in this Section 5.2 shall terminate and be of no further force and effect after the eighth (8th) anniversary of the Effective Date;
provided, that: 
 (i) if prior to such date Licensor has received Regulatory Approval for any products in the Retained Field which
are covered by any Licensed Patent(s), this Section 5.2(i) and the Competitive Infringement limitation shall continue in full force and effect with respect to all Licensed Patents; and 

(ii) if Licensor subsequently receives Regulatory Approval for any product(s) in the Retained Field that are covered by any Licensed
Patent(s), this Section 5.2(i) and the Competitive Infringement limitation on Licensee’s right to enforce shall be reinstated and again apply with respect to all enforcement of Licensed Patents by Licensee other than suits that are, as of
the time Licensor obtains such Regulatory Approval, already on file. 
 (j) The Indemnifying Party (defined in Section 7.2) shall
remain responsible to defend against and indemnify for Third Party Claims for which such party is responsible to indemnify under Section 7.1, even if arising in the context of counterclaim to a suit by the other party under this
Section 5.2. 
 *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted
version of this exhibit has been filed separately with the Commission. 
  

  
 12 

	6.	TERM; TERMINATION. 

 6.1. Term. This Agreement shall commence as of the Effective
Date and shall remain in effect (a) with respect to the Licensed Patents, until the expiration of the last to expire of the Licensed Patents, and (b) with respect to the Licensed Know-How, in perpetuity, provided that upon the
expiration of the last to expire of the Licensed Patents, the license granted to Licensee under the Licensed Know-How hereunder shall convert to a non-exclusive license. 

6.2. Termination for Breach. 

(a) Notice/Cures. Either party may terminate this Agreement for (i) the other party’s material breach of this Agreement, or
(ii) the other party’s material breach of the License and Covenant Agreement (a breach described in the foregoing clauses (i) and (ii) shall be referred to as a Material Breach), which remains uncured ninety (90) days
after the non-breaching party notified the breaching party in writing of the alleged Material Breach, describing with particularity the alleged Material Breach and explicitly stating that: the writing is a notice under this Section, the breach is a
Material Breach, and the breach must be cured within ninety (90) days in order for breaching party to retain its rights under this Agreement. Email shall not be deemed a writing for purpose of this Section 6.2. 

(b) Disputed Notices. 

(i) If a party gives notice of termination under Section 6.2(a) and the other party disputes whether such notice was proper (i.e., whether
the party having received such notice had actually materially breached this Agreement), then either party, by written notice to the other party, may refer such dispute for discussion by the following executive officers of each party: For Licensor,
the Chief Executive Officer, and for Licensee, an authorized officer at the level of Vice President or above. Each party shall make such officer or designee reasonably available for discussions with the other party’s such officer or designee,
and shall attempt in good faith through such discussions to resolve the dispute within ninety (90) days after a party refers the dispute for resolution by such officers. 

(ii) If such officers designated executive officers do not resolve such dispute within ninety (90) day period, then either party may
pursue any legal or equitable remedy available to it in accordance with Sections 9.9 and 9.11. 
 (iii) This Agreement shall remain in
effect pending the outcome of the resolution of such dispute. If as a result of such dispute resolution process it is finally determined that the notice of termination was proper, then the date of such final determination shall be deemed the date of
receipt of the notice of breach pursuant to Section 6.2(a) (and the ninety (90) day cure period shall commence beginning on the date of such final determination). If, however, as a result of such dispute resolution process it is determined
that the notice of termination was improper, then no material breach shall have occurred and this Agreement shall remain in effect. 
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 

  
 13 

 6.3. Effect of Termination. 

(a) Upon any termination (but not expiration), Licensee shall return to Licensor, or destroy, all technical information and materials developed
or used solely in connection with the Old Licensed Patents, New Licensed Patents, and/or Licensed Know-How (and not in connection with any other intellectual property rights of Licensee), including documents,
logs, notes, manuals, training materials, computer source codes, object codes, and any other information whether contained in written, electronic, or other media. 

(b) Upon any termination (but not expiration), Licensee will complete or terminate all outstanding tasks, including the provision of any
Licensed Products that have been contracted for by customers prior to notice of termination in a timely manner and in accordance with a mutually agreed schedule, but in any event within six (6) months from the effective date of termination of
this Agreement. 
 (c) The provisions of this Section 6 and of Sections 1, 4.2, 7, 8 and 9 shall survive any termination or
expiration of this Agreement. Nothing herein shall be construed to release either party of any obligation which matured prior to the effective date of such termination or expiration. 

 

	7.	RISK ALLOCATION. 

 7.1. Indemnification. 

(a) Licensor will defend, indemnify and hold harmless Licensee and its subsidiaries, parent corporations, Affiliates, officers, directors,
partners, employees, agents, successors and assigns (collectively, the Licensee Indemnitees) from and against any loss, damage, expense (including reasonable attorney’s fees of indemnitee(s) and those that may be asserted by a third
party) or liability (collectively, Losses) suffered by or imposed upon the Licensee Indemnitee(s) as a result of any claim, demand, action or proceeding by any third party (to avoid doubt, with “third party” meaning anyone
other than a party to this Agreement or an affiliate of a party to this Agreement) (each a Third Party Claim) arising from or related to (i) any breach of Licensor’s representations, warranties or covenants under this Agreement; and
(ii) any negligence or intentional misconduct by Licensor (or its agents, consultants or employees) in performing its obligations under this Agreement. The foregoing indemnification action shall not apply in the event and to the extent that a
claim is subject to indemnification by Licensee pursuant to Section 7.1(b) below, or a court of competent jurisdiction determines that such Losses arose as a result of any Licensee Indemnitee’s negligence, intentional misconduct or breach
of this Agreement. 
 (b) Licensee will defend, indemnify and hold harmless Licensor and its subsidiaries, parent corporations, Affiliates,
officers, directors, partners, employees, agents, successors and assigns (collectively, the Licensor Indemnitees) from and against any Losses suffered by or imposed upon the Licensor Indemnitee(s) as a result of any Third Party Claim
arising from or related to: (i) any breach of Licensee’s representations, warranties or covenants under this Agreement; (ii) any negligence or intentional misconduct by Licensee (or its agents, 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has
been filed separately with the Commission. 
  

  
 14 

 
consultants or employees) in performing its obligations under this Agreement; (iii) any claim that Licensee or its Affiliates (or any third party deriving rights through either of them)
infringes or misappropriates any Intellectual Property Right of a third party by their manufacture, having manufactured, offer for sale, sale, use, import or export of Licensed Products; and (iv) the use, promotion, sale or distribution of
Licensed Products by Licensee or its Affiliates (or any third party deriving rights through either of them). The foregoing indemnification action shall not apply in the event and to the extent a claim is subject to indemnification by Licensor
pursuant to Section 7.1(a) above, or that a court of competent jurisdiction determines that such Losses arose as a result of any Licensor Indemnitee’s negligence, intentional misconduct or breach of this Agreement. 

7.2. Procedure. To receive the benefit of the foregoing indemnities the Person seeking indemnification (the Indemnitee)
must promptly notify the other party (the Indemnifying Party) in writing of a claim or suit and provide reasonable cooperation (at the Indemnifying Party’s expense) and tender to the Indemnifying Party full authority to
defend or settle the claim or suit. The Indemnifying Party has no obligation to indemnify the Indemnitee in connection with any settlement made without the Indemnifying Party’s written consent. The Indemnifying Party may not settle such claim
or suit without the consent of the other party, which consent shall not be unreasonably withheld or delayed, provided, however, that such consent is not required so long as such settlement includes an unconditional release of the
Indemnitee, does not impose any obligations on any Indemnitee other than the payment of money damages fully indemnified hereunder, and in Licensee’s case meets the same standards as set forth in Section 5.2(i). The Indemnitee has the right
to participate at its own expense in the claim or suit and in selecting counsel therefor. The Indemnitee shall cooperate with the Indemnifying Party, as reasonably requested, at the Indemnifying Party’s sole cost and expense. If the parties
cannot agree as to the application of Sections 7.1(a) and 7.1(b) to any particular Third Party Claim, the parties may conduct separate defenses of such Third Party Claim. In such case, each party reserves the right to claim indemnity from the
other in accordance with Sections 7.1(a) and 7.1(b) upon resolution of such underlying Third Party Claim. 
 7.3. Limitation of
Liability. EXCEPT FOR BREACH OF OBLIGATIONS UNDER SECTION 5 OR SECTION 8 AND EXCEPT FOR AMOUNTS PAYABLE WITH RESPECT TO THIRD PARTY INDEMNIFICATION CLAIMS UNDER SECTION 7.1, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR LOST
PROFITS OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has
been filed separately with the Commission. 
  

  
 15 

	8.	CONFIDENTIALITY 

 8.1. Each party shall maintain the Confidential Information (defined
below in this Section 8.1) of the other party in trust and confidence and shall not disclose any such Confidential Information to any third party (except as expressly provided below) or use any such Confidential Information for any purposes
other than those necessary or permitted for performance under this Agreement (including for purposes of exercising the rights granted to it hereunder). Licensor’s “Confidential Information” shall be all of Licensor’s proprietary
and confidential information related to the Licensed Technology and/or New Licensed Patents disclosed by Licensor to Licensee in connection with activities under Section 5, including all proposed patent filings and information regarding any
potential infringement or misappropriation of the Licensed Technology and/or New Licensed Patents. Licensee’s “Confidential Information” shall be all of Licensee’s proprietary and confidential information related to its Licensed
Products disclosed by Licensee to Licensor in connection with activities under this Agreement. Neither party shall disclose Confidential Information of the other party to any employee, agent, consultant, or affiliate who does not have a reasonable
need for such information or who is not subject to binding obligations of confidentiality and limited use at least as restrictive in scope as those of this Section 8 (but may disclose to those who or that have such a reasonable need and are so
bound). Such obligations of confidentiality and limited use shall survive any termination of this Agreement for *** after the latest such expiration or termination. Each party shall use at least the same standard of care as it uses to protect its
own confidential information of a similar nature to prevent unauthorized disclosures or uses of Confidential Information of the other party, but no less than reasonable care. Each party shall promptly notify the other party upon discovery of any
unauthorized use or disclosure of the Confidential Information of the other party. 
 8.2. Confidential Information shall not include any
information which, as shown by competent proof: 
 (a) is now, or hereafter becomes, through no act or failure to act on the part of the
receiving party in breach hereof, generally known or available; 
 (b) is known by the receiving party at the time of receiving such
information, as shown by contemporaneous written records; 
 (c) is hereafter furnished to the receiving party by a third party, as a matter
of right and without restriction on disclosure; 
 (d) is independently developed by the receiving party without use of or reference to
Confidential Information of the other party, as shown by independent, contemporaneous written records; or 
 (e) is the subject of a prior,
express, written permission to disclose provided by the disclosing party. 
 *** = Portions of this exhibit have been omitted pursuant to a
request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

  
 16 

 8.3. The parties agree that the material terms of this Agreement will be considered Confidential
Information of both parties. Notwithstanding the foregoing, either party may disclose such terms (a) to bona fide potential corporate partners, potential investors or merger or acquisition partners, and to financial underwriters and legal and
financial advisors, provided that all such disclosures shall be made only to such Persons under binding written obligations of confidentiality and nonuse, and (b) to the extent required to comply with applicable legal requirements including as
part of regular securities law reporting requirements and/or in accordance with securities regulatory authority or securities exchange rules, demands and/or practice. If and when this Agreement is required to be publicly filed, the filing party
shall seek confidential treatment of information that it deems sensitive and for which it considers confidential treatment is reasonably legally available without risking liability. 

8.4. Notwithstanding any other provision of this Agreement, each party may disclose Confidential Information of the other party 

(a) to the extent and to the persons and entities required by an applicable governmental law, rule, regulation or order; provided, however,
that the responding party shall first have given prompt notice to the other party hereto to enable it to seek any available exemptions from or limitations on such disclosure requirement and shall reasonably cooperate in such efforts by the other
party; and 
 (b) to the extent and to the persons and entities required by rules of the National Association of Securities Dealers or any
stock exchange on which such party’s shares are traded. 
  

	9.	MISCELLANEOUS. 

 9.1. Relationship of Parties. For the purposes of this Agreement,
each party hereto shall be, and shall be deemed to be, an independent contractor and not an agent, partner, joint venturer, representative or employee of any other party. No party shall have authority to make any statements, representations,
compromises of rights or commitments of any kind, assume or create any obligations, or to accept process for or take any other action which shall be binding on the other parties, except as may be explicitly provided for herein or authorized in
writing by the other parties. 
 9.2. Notices. All notices, requests, claims, demands and other communications hereunder shall be in
writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by an internationally recognized overnight courier service, by facsimile, by e-mail or by registered or certified mail
(postage prepaid, return receipt requested) to the respective parties hereto at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 9.2): 

(a) if to Licensor: 
 Trivascular
Inc 
 3910 Brickway Boulevard 

Santa Rosa, CA 95403 
 Attention:
CEO 
 Fax: 707-541-3952 
 ***
= Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 

  
 17 

 with a copy (which shall not constitute notice) to an address to be specified by Licensor by
written notice to Licensee within ninety (90) days after the Effective Date (notices to Licensor prior to the time it provides this address shall not be required to be copied to this address). 

(b) if to Licensee: 
 Boston
Scientific Corporation 
 One Boston Scientific Place 

Natick, MA 01760 
 Attention:
General Counsel 
 Fax: 508-650-8956 

with a copy (which shall not constitute notice) to: 

Boston Scientific Scimed 
 One
Scimed Place 
 Maple Grove, MN 55311 

Attention: Chief Patent Counsel 

Fax: 763-494-2180 
 9.3.
Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect
for so long as the economic or legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to either party hereto. Upon such determination that any term or other provision is invalid, illegal
or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated
by this Agreement are consummated as originally contemplated to the greatest extent possible. 
 9.4. Entire Agreement. This
Agreement, the Purchase Agreement, the Confidentiality Agreement and the other Ancillary Agreements constitute the entire agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede all prior agreements and
undertakings, both written and oral, between the parties with respect to the subject matter hereof and thereof. 
 9.5. Assignment.
Licensor may not assign this Agreement or any of its rights and obligations under this Agreement without the prior written consent of the Licensee, not to be unreasonably withheld or delayed; provided, that (i) Licensor may assign this
Agreement as part of a corporate reorganization, consolidation, merger or sale of substantially all of the capital stock or assets of Licensor, or the relevant division or business unit of the party that holds or uses all or a substantial portion of
the Licensed Technology and/or New Licensed Patents without the prior written consent of the Licensee, and (ii) Licensor may assign this Agreement to any Affiliate of Licensor without the prior written consent of the Licensee, provided,
further, that in each instance the assignee Person expressly assumes all obligations imposed on the assigning party by this Agreement in writing. 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has
been filed separately with the Commission. 
  

  
 18 

 9.6. Amendment. This Agreement may not be amended or modified or waived except (a) by
an instrument in writing signed by a duly authorized officer (which shall include any Vice President) of each of Licensor and Licensee, or (b) by a waiver in accordance with Section 9.7. 

9.7. Waiver. Either party to this Agreement may (a) extend the time for the performance of any of the obligations or other acts of
the other party, (b) waive any inaccuracies in the representations and warranties of the other party contained herein or in any document delivered by the other party pursuant hereto or (c) to the extent permitted by applicable Law, waive
compliance with any of the agreements of the other party or conditions to such party’s obligations contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by a duly authorized officer
(which shall include any Vice President) of the party to be bound thereby. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other
term or condition of this Agreement. The failure of either party hereto to assert any of its rights hereunder shall not constitute a waiver of any of such rights. No email correspondence which does not specifically reference or waive this
Section 9.7 shall be deemed to waive rights under this Agreement. 
 9.8. No Third Party Beneficiaries. This Agreement shall be
binding upon and inure solely to the benefit of the parties hereto and their respective successors and permitted assigns and nothing herein is intended to or shall confer upon any other person any legal or equitable right, benefit or remedy of any
nature whatsoever, including any rights of employment for any specified period, under or by reason of this Agreement. 
 9.9. Other
Remedies; Specific Performance. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity upon
such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage may occur in the event that any provision of this Agreement is not performed in accordance
with its specific terms or is otherwise breached. It is accordingly agreed that the parties shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in
any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at Law or in equity. 

9.10. Interpretive Rules. The words “hereof,” “herein” and “hereunder” and words of similar import when
used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement, and all Article and Section references are to this Agreement unless otherwise specified. The words “include,”
“includes” and “including” will be deemed to be followed by the phrase “without 
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

  
 19 

 
limitation.” No implication shall be drawn from the inconsistent usage in this Agreement as to actual inclusion or non-inclusion of the phrase “without limitation” after
“include,” “includes” and “including.” The word “days” means calendar days unless otherwise specified herein. The headings contained in this Agreement are for reference purposes only and shall not affect in
any way the meaning or interpretation of this Agreement. No provision of this Agreement shall be construed to require either party or their respective officers, directors, subsidiaries or Affiliates to take any action which would violate or conflict
with any applicable Law. The word “if’ means “if and only if.” The word “or” shall not be exclusive. The meanings given to terms defined herein will be equally applicable to both the singular and plural forms of such
terms. Whenever the context may require, any pronoun includes the corresponding masculine, feminine and neuter forms. Except as otherwise expressly provided herein, all references to “dollars” or “$” will be deemed references to
the lawful money of the United States of America. 
 9.11. Governing Law. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of California without regard to its conflicts of laws rules. All Actions arising out of or relating to this Agreement shall be heard and determined primarily in the federal court courts of the Northern District
of California; provided, however, that if such federal court does not have jurisdiction over such Action, such Action shall be heard and determined primarily in any state court sitting in San Francisco, California. Consistent with the preceding
sentence, the parties hereto hereby (a) submit to the exclusive jurisdiction of any federal or state court sitting in the State of California for the purpose of any Action arising out of or relating to this Agreement brought by either party
hereto and (b) irrevocably waive, and agree not to assert by way of motion, defense, or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or
immune from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or that this Agreement or the transactions contemplated by this Agreement may not be enforced in or by any of the
above-named courts. Each party further irrevocably consents to the service of process out of any of the aforementioned courts in any such Action by the mailing of copies thereof by mail to such party at its address set forth in this Agreement, such
service of process to be effective upon acknowledgment of receipt by registered mail; provided, however, that nothing in this Section 9.11 shall affect the right of any party to serve legal process in any other manner permitted by law. The
consent to jurisdiction set forth in this Section 9.11 shall not constitute a general consent to service of process in the State of California and shall have no effect for any purpose except as provided in this Section 9.11. 

9.12. Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY WANES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY
HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH OF THE PARTIES HERETO HEREBY (A) CERTIFIES THAT NO
REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, 
 *** = Portions of this exhibit have been
omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

  
 20 

 
THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE
TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 9.12. 

9.13. Counterparts. This Agreement may be executed and delivered (including by facsimile transmission) in one or more counterparts, and
by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement. 

9.14. Further Assurances. At any time and from time to time, either party will, without further consideration and at the other
party’s expense, take such further action and execute and deliver such further instruments and documents as may be reasonably requested by the other party in order to carry out the provisions and purposes of this Agreement. 

9.15. No Implied Rights. No implied rights of any kind under or with respect to Intellectual Property Rights are granted or shall be
deemed to have been granted under this Agreement. Each party only grants those rights and licenses that are explicitly granted in this Agreement. 

[The remainder of this page intentionally left blank.] 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has
been filed separately with the Commission. 
  

  
 21 

 IN WITNESS WHEREOF, each of Licensor and Licensee has caused this Agreement to be executed as of
the date first written above by their respective officers thereunto duly authorized. 
  

									
	BOSTON SCIENTIFIC SCIMED, INC.	  		  	Boston Scientific Santa Rosa Corp., which was previously known as TriVascular, Inc., a California corporation, that will be known as Trivascular 2, Inc. (after a name change to occur shortly after the Effective
Date)
					
	By:	 	 /s/ Paul LaViolette
	  		  	By:	 	 /s/ Michael Chobotov

	Name:	 	 Paul LaViolette
	  		  	Name:	 	 Michael Chobotov

	Title:	 	 CEO and President
	  		  	Title:	 	 Chief Executive Officer

 [Signature Page to Exclusive License Agreement] 

  

 EXHIBIT A 

LICENSED KNOW-HOW 
 General:

 The Assigned Know-How (as defined in the Know-How Agreement). 

 Fi

ll/Film Know-How: 
 That subset of the Assigned Know-How that constitutes a fill material
or a PTFE film, or a method of making forming or using either of the foregoing.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]